1. Home
  2. BIO vs GDS Comparison

BIO vs GDS Comparison

Compare BIO & GDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIO
  • GDS
  • Stock Information
  • Founded
  • BIO 1952
  • GDS 2001
  • Country
  • BIO United States
  • GDS China
  • Employees
  • BIO N/A
  • GDS N/A
  • Industry
  • BIO Biotechnology: Laboratory Analytical Instruments
  • GDS Computer Software: Programming Data Processing
  • Sector
  • BIO Industrials
  • GDS Technology
  • Exchange
  • BIO Nasdaq
  • GDS Nasdaq
  • Market Cap
  • BIO 7.7B
  • GDS 7.4B
  • IPO Year
  • BIO N/A
  • GDS 2016
  • Fundamental
  • Price
  • BIO $297.20
  • GDS $37.35
  • Analyst Decision
  • BIO Strong Buy
  • GDS Strong Buy
  • Analyst Count
  • BIO 4
  • GDS 7
  • Target Price
  • BIO $333.50
  • GDS $47.51
  • AVG Volume (30 Days)
  • BIO 214.4K
  • GDS 3.9M
  • Earning Date
  • BIO 10-29-2025
  • GDS 11-18-2025
  • Dividend Yield
  • BIO N/A
  • GDS N/A
  • EPS Growth
  • BIO N/A
  • GDS N/A
  • EPS
  • BIO 11.49
  • GDS 3.46
  • Revenue
  • BIO $2,554,200,000.00
  • GDS $1,526,241,101.00
  • Revenue This Year
  • BIO $2.12
  • GDS $13.40
  • Revenue Next Year
  • BIO $2.90
  • GDS $14.00
  • P/E Ratio
  • BIO $25.93
  • GDS $190.46
  • Revenue Growth
  • BIO N/A
  • GDS 10.29
  • 52 Week Low
  • BIO $211.43
  • GDS $16.93
  • 52 Week High
  • BIO $387.99
  • GDS $52.50
  • Technical
  • Relative Strength Index (RSI)
  • BIO 58.13
  • GDS 48.80
  • Support Level
  • BIO $266.71
  • GDS $39.09
  • Resistance Level
  • BIO $286.84
  • GDS $43.88
  • Average True Range (ATR)
  • BIO 8.86
  • GDS 2.35
  • MACD
  • BIO 2.64
  • GDS -0.23
  • Stochastic Oscillator
  • BIO 71.98
  • GDS 0.61

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

About GDS GDS Holdings Limited ADS

GDS Holdings started as an IT service provider in 2001 then moved to the data center business with its first self-developed data center opening in 2010. The company now develops and operates data centers in China and also builds, operates and transfers data centers for other clients. It offers colocation and managed services and mainly targets hyperscale cloud service customers who take large areas of its data centers or even whole data centers under long-term contracts. Its data centers are located predominantly in and around the Tier 1 cities in China and it has also started an expanding into Southeast Asia via the now 38% owned DayOne. GDS listed on the Nasdaq in 2016 and completed a secondary listing in Hong Kong in 2020.

Share on Social Networks: